Merck and Broad Institute announce CRISPR license agreement
Merck and the Broad Institute have signed an agreement on the granting of non-exclusive intellectual property licenses to CRISPR-based genome editing.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
Entries by Thomas Gabrielczyk
Controlled human malaria infection trials
Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
European Biotechnology Guide now available on app!
The European Biotechnology Science & Industry Guide provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry, and is now also available as part of the BIOCOM app!
Making every cent in testing count
It’s no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
Bioeconomy: just a way to set up a smarter agriculture?
Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
Biotech company Galapagos improves high-content screening (HCS) in scleroderma with IN Carta Phenoglyphs image analysis
Galapagos’s mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary healthy andpatient cells, the company discovers which proteins play a key role in diseases such as rheumatoid arthritis, inflammatory bowel disease, and fibrosis.
Boehringer Ingelheim and Yuhan Corp. in US$870m NASH deal
Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay $40m upfront and in near-term payments to acquire the commercialisation rights to the compound. Under the agreement, Yuhan Corp. is eligible to receive up to USD 830 million in potential milestone payments plus tiered royalties on future net sales.
Smart bra set to detect breast cancer
A French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography.
Trilogue put lights on green for Horizon Europe
The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliament’s proposal to increase its budget from €100bn to €120bn.
GARDP wants five AMR breakers by 2025
GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025.